Adrenocortical Carcinoma Adrenal Tumor - Pipeline Review, Q2 2011

Description: Adrenocortical Carcinoma Adrenal Tumor - Pipeline Review, Q2 2011

Summary

Global Markets Direct's, 'Adrenocortical Carcinoma Adrenal Tumor - Pipeline Review, Q2 2011', provides an overview of the Adrenocortical Carcinoma Adrenal Tumor therapeutic pipeline. This report provides information on the therapeutic development for Adrenocortical Carcinoma Adrenal Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Adrenocortical Carcinoma Adrenal Tumor. 'Adrenocortical Carcinoma Adrenal Tumor - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note:- Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Adrenocortical Carcinoma Adrenal Tumor.
- A review of the Adrenocortical Carcinoma Adrenal Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Adrenocortical Carcinoma Adrenal Tumor pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Adrenocortical Carcinoma Adrenal Tumor.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Adrenocortical Carcinoma Adrenal Tumor pipeline depth and focus of Adrenocortical Carcinoma Adrenal Tumor therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Adrenocortical Carcinoma Adrenal Tumor Overview
Therapeutics Development
An Overview of Pipeline Products for Adrenocortical Carcinoma Adrenal Tumor
Adrenocortical Carcinoma Adrenal Tumor Therapeutics under Development by Companies
Adrenocortical Carcinoma Adrenal Tumor Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Adrenocortical Carcinoma Adrenal Tumor Therapeutics - Products under Development by Companies
Adrenocortical Carcinoma Adrenal Tumor Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Adrenocortical Carcinoma Adrenal Tumor Therapeutics Development
Astellas Pharma Inc.
Pfizer Inc.
BTG International Ltd
Neotropix, Inc.
AstraZeneca AB
Adrenocortical Carcinoma Adrenal Tumor - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Axitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OSI-906 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NTX-010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
R935788 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RAD001 + Vatalanib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Iressa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OncoGel + Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Doxorubicin + Tamoxifen + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zactima + Velcade - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oxaliplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Suramin + Hydrocortisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sutent - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RAD001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Streptozocin + Mitotane - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sorafenib + Paclitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Pegfilgrastim + Cisplatin + Doxorubicin + Etoposide + Mitotane - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Doxorubicin + Vincristine + Etoposide + Mitotane - Drug Profile
Product Description
Mechanism of Action
R&D Progress
temsirolimus + Vinorelbine Ditartrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
doxorubicin hydrochloride + etoposide + mitotane + tariquidar + vincristine sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sunitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cixutumumab + temsirolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AT-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adrenocortical Carcinoma Adrenal Tumor Therapeutics – Drug Profile Updates
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Adrenocortical Carcinoma Adrenal Tumor, Q2 2011
Products under Development for Adrenocortical Carcinoma Adrenal Tumor – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Astellas Pharma Inc., 2011
Pfizer Inc., 2011
BTG International Ltd, 2011
Neotropix, Inc., 2011
AstraZeneca AB, 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Adrenocortical Carcinoma Adrenal Tumor Therapeutics – Drug Profile Updates

List of Figures
Number of Products under Development for Adrenocortical Carcinoma Adrenal Tumor, Q2 2011
Products under Development for Adrenocortical Carcinoma Adrenal Tumor – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011

Ordering:

Order Online - http://www.researchandmarkets.com/reports/1801416/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit

http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Adrenocortical Carcinoma Adrenal Tumor - Pipeline Review, Q2 2011
Web Address: http://www.researchandmarkets.com/reports/1801416/
Office Code: SCD2ST9O

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td></td>
<td>USD 500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td></td>
<td>USD 1000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td></td>
<td>USD 1500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr □ Mrs □ Dr □ Miss □ Ms □ Prof □
First Name: ______________________ Last Name: ______________________
Email Address: * ______________________
Job Title: ______________________
Organisation: ______________________
Address: ______________________
City: ______________________
Postal / Zip Code: ______________________
Country: ______________________
Phone Number: ______________________
Fax Number: ______________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB9853308331083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp